Posted by Michael Wonder on 23 Apr 2019
Additional embargo period following revised CDEC recommendations
17 April 2019 - Effective immediately, CADTH has revised its procedures for the CADTH Common Drug Review to permit an additional embargo period for CADTH Canadian Drug Expert Committee (CDEC) recommendations that have been substantially revised following a request for reconsideration by a manufacturer or a request for clarification by the participating drug plans.
This process will apply in following circumstances:
- An initial embargoed CDEC recommendation stating that a drug not be reimbursed is revised to state that the drug should be reimbursed with or without conditions.
- An initial embargoed CDEC recommendation stating that a drug should be reimbursed with or without conditions is revised to state that the drug should not be reimbursed.
